ClinicalTrials.gg
CompletedNCT01721733Updated Aug 31, 2020

Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome

A Phase 2 interventional study of Placebo and EPI-743 15 mg/kg in Leigh Syndrome, sponsored by PTC Therapeutics. Completed at 4 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-08-31.

Sponsored by PTC Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Leigh Disease with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Leigh Disease · United States.

Started
2012
with 2 others
Phase 2
5 of 14
1 open now
Registered
4th of 14
by date
Lead sponsor
5 of 14
PTC Therapeutics

Among the 14 studies in Leigh Disease with a site in United States, this one is one of 3 that started in 2012, is one of 5 in phase 2, and was the 4th registered.

Leigh Disease

20 studies on the registry are indexed under Leigh Disease; 9 are open to participants now.

Browse Leigh Disease studies →

Open to participants now

6 of the 14 studies in Leigh Disease with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Leigh Disease studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Leigh Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of EPI-743 in children with Leigh syndrome on disease severity, neuromuscular function, respiratory function, disease morbidity and mortality and disease associated biomarkers.

Read the detailed description

The purpose of this study is to evaluate the effects of EPI-743 in patient with Leigh syndrome on disease severity, neuromuscular function, respiratory function, disease morbidity and mortality and biomarkers associated with the disease.

This study is a six month prospective randomized double-blind, placebo-controlled trial with a six month extension phase of two dose levels of EPI743. The planned enrollment is for approximately 30 children with genetically confirmed Leigh syndrome. After 6 months of treatment, those children that were randomized to the placebo treatment arm will be re-randomized to one of the 2 active treatment arms.

03

Conditions studied

  • Leigh Syndrome

Keywords

  • EPI743
  • Leigh syndrome
  • respiratory chain disease
  • mitochondrial disorders
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical and MRI diagnosis of Leigh syndrome
  • Moderate disease severity based on NPMDS score
  • Age under 18 years
  • Documented evidence of disease progression within 12 month of enrollment
  • Availability of MRI that confirms necrotizing encephalopathy
  • Patient or guardian able to consent and comply with protocol requirements
  • Abstention from Coenzyme Q10, Vitamins C \& E, lipoic acid and Idebenone

Exclusion criteria

Exclusion Criteria:

  • Allergy to EPI-743, Vitamin E or sesame oil
  • History of bleeding abnormalities or abnormal PT/
  • Diagnosis of concurrent inborn error of metabolism
  • Previous tracheostomy
  • Ventilator dependent or use of noninvasive ventilatory support w/in 1 month of enrollment
  • LFTs greater than 2 times
  • Renal insufficiency
  • End stage cardiac failure
  • Fat malabsorption syndrome
  • Use of anticoagulant medications
  • Abstention from Botox for 6 months prior to enrollment and for duration of study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Each patient will receive a volume of placebo based on weight

    Drug: Placebo

  • Active comparator
    EPI-743 15 mg/kg

    Each subjects dose will be based on their weight. 15 mg/kg with a maximum dose of 200 mg per dose, t.i.d., will be administered in this treatment arm.

    Drug: EPI-743 15 mg/kg

  • Active comparator
    EPI-743 5 mg/kg

    Each subjects dose will be based on their weight. 5 mg/kg with a maximum dose of 100 mg per dose, t.i.d., will be administered in this treatment arm.

    Drug: EPI-743 5 mg/kg

Interventions

06

What researchers measure

Primary outcomes

  1. Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) Sections 1-3

    Change from baseline to six months will be compared between subjects in active treatment group and placebo group

    Time frame: 6 months

Secondary outcomes

  1. Neuromuscular function

    Gross Motor Function Measure; Barry Albright Dystonia Scale

    Time frame: 6 months

  2. Respiratory function

    Need for tracheostomy

    Time frame: 6 months

  3. Disease morbidity

    Total number of hospitalizations

    Time frame: 6 months

  4. Glutathione cycle biomarkers

    Blood levels of glutathione will be compared between placebo and treatment group

    Time frame: 6 months

  5. Number of dose limiting serious adverse events

    Time frame: 6 months

  6. Mortality

    Number of deaths

    Time frame: 6 months

07

Study locations

4 sites
  • Stanford University
    Palo Alto, California 94304, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2012 to primary completion in Feb 2015, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2012
First posted
Nov 6, 2012
StartActual
Oct 31, 2012
Primary completionActual
Feb 28, 2015
CompletionActual
May 31, 2015
Results delay requested
Aug 17, 2020
Last update
Aug 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01721733
Lead sponsor
PTC Therapeutics
Collaborators
Axio Research. LLC
Responsible party
Sponsor
First posted
Nov 6, 2012
Start date
Oct 31, 2012
Primary completion
Feb 28, 2015
Completion
May 31, 2015
Last update
Aug 31, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha-tocotrienol quinone

Start the discussion